University of Nebraska Medical Center, Omaha, Nebraska, USA.
Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
J Infect Dis. 2021 Nov 22;224(10):1765-1774. doi: 10.1093/infdis/jiab210.
Immune activation persists despite suppressive antiretroviral therapy (ART) and may be affected by sex or body composition. We explored these relationships in a subset of participants who initiated ART in two large randomized trials.
Purposeful sampling selected participants who achieved virologic suppression on ART and either maintained weight within ± 0.5 kg/m2 or gained 2.6-6.4 kg/m2 from baseline to 96 weeks. We measured 7 markers of inflammation and immune activation at weeks 0 and 96. Multivariable linear regression explored associations of weight gain, sex, and pre-ART BMI with pre-ART and changes in biomarker concentrations.
340 participants were selected; median pre-ART age 42 years, CD4+ cell count 273 cells/mm3, HIV-1 RNA 4.7 log10 copies/mL; 49% were women, 33% white, 42% black, and 24% Hispanic. Among participants with a normal pre-ART BMI, higher pre-ART levels of IL-6, sTNF-RI and RII, CXCL-10, sCD163 and hsCRP were associated with weight gain. Association of weight gain with week 96 changes of these biomarkers differed by sex; women who gained weight had smaller declines in most measured biomarkers compared to men who gained.
Among women, weight gain is associated with attenuated decline in several immune activation markers following ART initiation. Clinical Trials Registration. NCT00811954 and NCT00811954.
尽管接受了抑制性抗逆转录病毒疗法(ART),免疫激活仍持续存在,并且可能受到性别或身体成分的影响。我们在两项大型随机试验中启动 ART 的参与者亚组中探索了这些关系。
有目的的抽样选择了那些在 ART 下实现病毒学抑制并且在 96 周时体重保持在±0.5 kg/m2 或从基线增加 2.6-6.4 kg/m2 的参与者。我们在 0 周和 96 周时测量了 7 种炎症和免疫激活标志物。多变量线性回归探索了体重增加、性别和 ART 前 BMI 与生物标志物浓度的变化的相关性。
选择了 340 名参与者;中位 ART 前年龄为 42 岁,CD4+细胞计数为 273 个细胞/mm3,HIV-1 RNA 为 4.7 log10 拷贝/mL;49%为女性,33%为白人,42%为黑人,24%为西班牙裔。在 ART 前 BMI 正常的参与者中,较高的 IL-6、sTNF-RI 和 RII、CXCL-10、sCD163 和 hsCRP 水平与体重增加相关。体重增加与这些生物标志物在第 96 周的变化之间的关联因性别而异;与男性相比,体重增加的女性在大多数测量的生物标志物中的下降幅度较小。
在女性中,体重增加与 ART 启动后几种免疫激活标志物的衰减下降有关。临床试验注册。NCT00811954 和 NCT00811954。